Insights Into the Characteristics of Sweet Syndrome in Patients With and Without Hematologic Malignancy

Frontiers in Medicine
Siting ZhengHong Fang

Abstract

Background: Sweet syndrome is a neutrophilic dermatosis that could be associated with malignancy, especially hematologic malignancy. Few studies have systematically elaborated on this disorder and its features related with hematologic malignancy. Objective: This study aimed to describe the clinicopathological characteristics, treatment, and outcome of Sweet syndrome and to evaluate patient characteristics associated with hematologic malignancy. Methods: We retrospectively reviewed patients with Sweet syndrome at the Department of Dermatology, the First Affiliated Hospital of Zhejiang University from October 2010 to February 2019. Results: The study included 37 patients (16 men and 21 women), with a mean age of 53 years. Ten patients (27%) were classified as having malignancy-associated Sweet syndrome: nine with a hematologic malignancy including acute myeloid leukemia (4/9, 44%), myelodysplastic syndrome (4/9, 44%), and multiple myeloma (1/9, 11%) and one with a solid tumor diagnosed with liver carcinoma. The mean hemoglobin and platelet levels (P = 0.007 and P = 0.013, respectively), were significantly lower in patients with hematologic malignancy than in those with Sweet syndrome only. No significant difference in histopathol...Continue Reading

References

Oct 1, 1994·Journal of the American Academy of Dermatology·P von den Driesch
Aug 1, 1964·The British Journal of Dermatology·R D SWEET
Feb 21, 2006·Journal of the American Academy of Dermatology·Paul S YamauchiJ Mark Jackson
Feb 16, 2007·The British Journal of Dermatology·C Y NeohS K Ng
Jul 28, 2007·Orphanet Journal of Rare Diseases·Philip R Cohen
Jan 15, 2008·Annals of the Rheumatic Diseases·A DellucP Cacoub
Apr 6, 2011·Dermatology : International Journal for Clinical and Investigative Dermatology·Nicolas KlugerDidier Bessis
Oct 12, 2011·Anais Brasileiros De Dermatologia·Mayra Carrijo RochaelKarla Strong Rodrigues
Oct 23, 2012·Annals of the Rheumatic Diseases·Troels HerlinPolly J Ferguson
Apr 3, 2013·International Journal of Oncology·Shahzad RazaCarl Freter
Jul 31, 2013·Journal of the American Academy of Dermatology·Nicole M RochetLawrence E Gibson
Jan 30, 2015·Clinical Lymphoma, Myeloma & Leukemia·Syed M KazmiJorge Cortes
Mar 12, 2016·International Journal of Dermatology·Meriem AmouriHamida Turki
Mar 31, 2016·JAMA Dermatology·Ashwin AgarwalMatilda W Nicholas
Mar 16, 2017·JAMA Dermatology·Victoria Alegría-LandaLuis Requena
Mar 17, 2017·Journal of Cutaneous Medicine and Surgery·Jose Ricardo Casarin CostaCyro Festa Neto
Nov 7, 2017·Journal of the American Academy of Dermatology·Caroline A NelsonMisha Rosenbach
Feb 24, 2018·Journal of Crohn's & Colitis·C Moreno MárquezL Castro Laria
Feb 28, 2018·Open Access Macedonian Journal of Medical Sciences·Claudio GuarneriGeorgi Tchernev
Apr 14, 2018·Journal of the American Academy of Dermatology·Caroline A NelsonMisha Rosenbach
Apr 2, 2019·Frontiers in Immunology·Michael S Heath, Alex G Ortega-Loayza
Jul 3, 2019·Curēus·Zainab ShahidRohit Jain

❮ Previous
Next ❯

Citations

Dec 29, 2020·Clinical Case Reports·Asmaa FerdjallahChristen L Ebens
Jun 5, 2021·Scientific Reports·Rebeca Escutia-GutiérrezJuan Armendáriz-Borunda
Apr 24, 2021·Journal of Crohn's & Colitis·Joseph SleimanFlorian Rieder

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
bone marrow aspiration
surgical resection
MDS
ESR

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Journal of the American Academy of Dermatology
Nicole M RochetLawrence E Gibson
Medicina clínica
María Luisa Martínez MartínezMaría Gómez Sanchez
La Revue du praticien
Louise HefezOlivier Fain
© 2021 Meta ULC. All rights reserved